BNGO PE Ratio & Valuation,Is BNGO Overvalued

BNGO Relative Valuation

BNGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNGO is overvalued; if below, it's undervalued.

Historical Valuation

Bionano Genomics Inc (BNGO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.47 is considered Undervalued compared with the five-year average of -6.77. The fair price of Bionano Genomics Inc (BNGO) is between 76.62 to 77.36 according to relative valuation methord. Compared to the current price of 1.56 USD , Bionano Genomics Inc is Undervalued By 97.96%.

Relative Value

Fair Zone

76.62-77.36

Current Price：1.56

97.96%

Undervalued

-0.45

0.00

EV/EBITDA

Bionano Genomics Inc. (BNGO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -6.47. The thresholds are as follows: Strongly Undervalued below -29.79, Undervalued between -29.79 and -18.13, Fairly Valued between 5.20 and -18.13, Overvalued between 5.20 and 16.86, and Strongly Overvalued above 16.86. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.45

EV/EBIT

Bionano Genomics Inc. (BNGO) has a current EV/EBIT of -0.45. The 5-year average EV/EBIT is -6.31. The thresholds are as follows: Strongly Undervalued below -28.22, Undervalued between -28.22 and -17.26, Fairly Valued between 4.65 and -17.26, Overvalued between 4.65 and 15.61, and Strongly Overvalued above 15.61. The current Forward EV/EBIT of -0.45 falls within the Historic Trend Line -Fairly Valued range.

0.47

Bionano Genomics Inc. (BNGO) has a current PS of 0.47. The 5-year average PS is 23.18. The thresholds are as follows: Strongly Undervalued below -53.89, Undervalued between -53.89 and -15.35, Fairly Valued between 61.72 and -15.35, Overvalued between 61.72 and 100.25, and Strongly Overvalued above 100.25. The current Forward PS of 0.47 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Bionano Genomics Inc. (BNGO) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.80. The thresholds are as follows: Strongly Undervalued below -6.17, Undervalued between -6.17 and -3.98, Fairly Valued between 0.39 and -3.98, Overvalued between 0.39 and 2.57, and Strongly Overvalued above 2.57. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Bionano Genomics Inc. (BNGO) has a current P/FCF of 0.00. The 5-year average P/FCF is 22.40. The thresholds are as follows: Strongly Undervalued below -174.69, Undervalued between -174.69 and -76.15, Fairly Valued between 120.94 and -76.15, Overvalued between 120.94 and 219.48, and Strongly Overvalued above 219.48. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Bionano Genomics Inc (BNGO) has a current Price-to-Book (P/B) ratio of 0.32. Compared to its 3-year average P/B ratio of 0.63 , the current P/B ratio is approximately -49.87% higher. Relative to its 5-year average P/B ratio of 3.99, the current P/B ratio is about -92.04% higher. Bionano Genomics Inc (BNGO) has a Forward Free Cash Flow (FCF) yield of approximately -113.28%. Compared to its 3-year average FCF yield of -265.23%, the current FCF yield is approximately -57.29% lower. Relative to its 5-year average FCF yield of -162.07% , the current FCF yield is about -30.11% lower.

0.30

P/B

Median3y

0.63

Median5y

3.99

-113.28

FCF Yield

Median3y

-265.23

Median5y

-162.07

Competitors Valuation Multiple

The average P/S ratio for BNGO's competitors is 0.00, providing a benchmark for relative valuation. Bionano Genomics Inc Corp (BNGO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 21.31%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of BNGO decreased by 91.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.07M to 7.37M.

The secondary factor is the P/E Change, contributed -28.25%to the performance.

Overall, the performance of BNGO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

21.31%

6.07M → 7.37M

Revenue Growth

-84.16%

-728.57 → -115.42

Margin Expansion

-28.25%

-0.18 → -0.13

P/E Change

-91.10%

17.30 → 1.54

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Bionano Genomics Inc (BNGO) currently overvalued or undervalued?

What is Bionano Genomics Inc (BNGO) fair value?

BNGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bionano Genomics Inc (BNGO) is between 76.62 to 77.36 according to relative valuation methord.

How does BNGO's valuation metrics compare to the industry average?

What is the current P/B ratio for Bionano Genomics Inc (BNGO) as of Dec 16 2025?

As of Dec 16 2025, Bionano Genomics Inc (BNGO) has a P/B ratio of 0.32. This indicates that the market values BNGO at 0.32 times its book value.

What is the current FCF Yield for Bionano Genomics Inc (BNGO) as of Dec 16 2025?

As of Dec 16 2025, Bionano Genomics Inc (BNGO) has a FCF Yield of -113.28%. This means that for every dollar of Bionano Genomics Inc’s market capitalization, the company generates -113.28 cents in free cash flow.

What is the current Forward P/E ratio for Bionano Genomics Inc (BNGO) as of Dec 16 2025?

As of Dec 16 2025, Bionano Genomics Inc (BNGO) has a Forward P/E ratio of -0.47. This means the market is willing to pay $-0.47 for every dollar of Bionano Genomics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bionano Genomics Inc (BNGO) as of Dec 16 2025?

As of Dec 16 2025, Bionano Genomics Inc (BNGO) has a Forward P/S ratio of 0.47. This means the market is valuing BNGO at $0.47 for every dollar of expected revenue over the next 12 months.

BNGO Valuation

BNGO Valuation

BNGO Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Bionano Genomics Inc (BNGO) currently overvalued or undervalued?

What is Bionano Genomics Inc (BNGO) fair value?

How does BNGO's valuation metrics compare to the industry average?

What is the current P/B ratio for Bionano Genomics Inc (BNGO) as of Dec 16 2025?

What is the current FCF Yield for Bionano Genomics Inc (BNGO) as of Dec 16 2025?

What is the current Forward P/E ratio for Bionano Genomics Inc (BNGO) as of Dec 16 2025?

What is the current Forward P/S ratio for Bionano Genomics Inc (BNGO) as of Dec 16 2025?